Emit II Plus Oxycodone Assay
Enabling early detection of pain prescription abuse
The Centers for Disease Control and Prevention estimates that the total economic burden of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.1
Oxycodone is a semisynthetic opioid analgesic prescribed for the relief of moderate to severe pain. Oxycodone structurally resembles codeine and morphine, with similar analgesic properties and potential for addiction and abuse. Oxycodone is a DEA schedule II drug. The drug oxycodone is prescribed in controlled-release form (OXYCONTIN), or in combination with acetaminophen (PERCOCET) or with aspirin (PERCODAN).
Features & Benefits
The Emit II Plus Oxycodone assay offers 100 ng/mL and 300 ng/mL cutoffs and no cross-reactivity to structurally related compounds such as buprenorphine and hydrocodone.
- Achieve high specificity for oxycodone and oxymorphone to provide confidence for accurate results while meeting the SAMHSA requirements for oxycodone screening
- Reduce false results with an assay that has 98% agreement to LC-MS/MS for positive samples and 100% agreement for negatives.1
- Consolidate opioid testing with other Siemens Healthineers assays, enabling providers to screen patients on one trusted system
EMIT II Plus Oxycodone Assay Performance*
Homogeneous enzyme immunoassay
12 µL (100 ng/mL)
50—400 ng/mL (100 ng/mL cutoff)
Stable unopened or opened until exp., when stored refrigerated at 2–8°C
100 ng/mL and 300 ng/mL
0, 100, 300, 500, 1000 ng/mL
Limit of Detection
29 ng/mL (100 ng/mL cutoff)
Cutoff Overlap Precision
0% overlap between cutoff and ±25% controls
Onboard Reagent Stability
As indicated by QC results
1 Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016;54(10):901-906. doi:10.1097/MLR.0000000000000625.
* Future availability cannot be guaranteed